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Abstract
Purpose. The purpose of this study was to evaluate: (1) the correlation between grade and ploidy or S-phase fraction (SPF),
(2) the prognostic value of DNA ¯ ow cytometric study in soft tissue sarcomas.
Patients/Methods. In all, 47 tissue samples from soft tissue sarcoma patients, surgically treated in the same center, were
included. Flow cytometric analyses were performed according to a modi® ed version of the original method of Hedley et al.
Results. DNA ploidy status could be determined in 44 samples out of 47 (success rate 94%). Of these 44, S-phase fraction
could be calculated in 34 samples (77%). In the study group as a whole, aneuploidy was signi® cantly correlated with high
grade. Survival analyses were carried out in 21 patients with soft tissue sarcoma, all surgically treated in the same center,
without chemotherapy or radiotherapy. In univariate analyses, DNA ploidy was found to be a signi® cant factor for overall
survival (OAS) and metastasis-free survival MFS. Mean OAS for aneuploid tumors and diploid tumors were 35 and 65
months (p=0.034), and mean MFS 23 and 61 months, respectively (p=0.005).
Discussion. There is a relation between histological grade and ploidy in soft tissue sarcomas. It appears that low-grade
tumors are generally diploid, whereas high-grade tumors tend to be aneuploid. In a subgroup of patients treated only with
surgery, DNA ploidy was found to be an important factor for predicting OAS and MFS.
Key words: sarcoma, DNA analysis, ¯ ow cytometry, prognosis
Introduction
Sarcomas are a heterogeneous group of tumors
causing diagnostic and therapeutic difficulties.
1,2The
mainstay of therapy is surgery. Adjuvant
chemotherapy has been shown to be effective in pedi-
atric rhabdomyosarcoma, osteosarcoma and Ewing’s
sarcoma but remains controversial in the other adult
sarcomas.
3± 5 It is important to identify the subset of
patients with a poor prognosis because they are
candidates for experimental adjuvant chemotherapy
regimens in ongoing studies. Unfortunately this selec-
tion is not easy and hampered by the heterogeneity of
morphology and clinical behavior. Tumor size,
histological grade, localization, tumor necrosis,
vascular invasion, clinical and pathologic response to
neoadjuvant chemotherapy, age and sex, have been
all proposed to be prognostic factors for sarcomas.
6± 8
Among them, histological grade and tumor size are
universally accepted as important factors and most
adjuvant trials use a combination of these two factors
for patient selection. Unfortunately histological grade
of sarcomas has low reproducibility.
9± 11
Flow cytometric analysis of ploidy and S-phase
fraction (SPF) has been shown to be useful in
prognostication in various tumors.
12Such studies have
also been done for sarcomas and some have found it
to be an independent prognostic factor. In some
studies it was also shown that ¯ ow cytometric analysis
could help in grading these tumors.
13± 18
In this study we aimed to evaluate: (1) correlation
between grade and ploidy or S-phase fraction, and
(2) the prognostic value of DNA ¯ ow cytometric
study in adult soft tissue sarcomas.
Patients and methods
Patients
Patients with histologically proven soft tissue sarcomas
between 1989 and 1998 in the Ankara University
Faculty of Medicine, Ibni-Sina Hospital, were
included in the study. The paraffin-embedded tissue
samples of patients were re-evaluated by the same
pathologist, for diagnostic veri® cation and grading.
Patients with diagnostic and grading disparance were
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with soft tissue sarcoma were selected for study.
Patient characteristics, treatment and follow up were
noted. Patient characteristics are shown in Table 1.
Method
Flow cytometric analyses were performed according
to principles of a modi® ed version of the original
method of Hedley et al.
19First, histological specimens
with Hemotoxylin± eosin were evaluated. From tissues
composed of at least 20% malignant cells, 5± 6 sections
of 50 m m were cut. Areas with tumor necrosis were
avoided.The sections were deparaffinized with xylene
and rehydrated by changing concentrations of ethanol:
100%, 100%, 95%, 70% and 50%, respectively. After
overnight resting in distilled water, the tissue was
washed twice with phosphate-buffered saline (PBS).
The pieces were digested with 1 mg/ml protease
(Sigma Type XXIV) at 37Ê C for 60 min, shaking by
hand every 5± 10 min. Following the digestion, 2 ml
of cold PBS was added to the solution.The solution
was ® ltered through a 37-m m nylon mesh. After two
washings with cold PBS, cell suspensions having
53 10
5 to 13 10
6 nuclei per ml were prepared with
trypsin buffer and centrifuged, then the nuclei were
incubated with RNAse solution for 10 min. Finally
the nuclear suspensions were stained with propidium
iodide and kept in the dark for at least 10 min at 4Ê C.
The samples were then ® ltered thorough a 37-m m
nylon mesh before cytometric analysis.
DNA analyses were carried out with a FACSort
¯ ow cytometry (Becton & Dickinson FACSort).
Excitation of propidium iodide occurred at 488 nm.
At least 20 000 nuclei from each specimen were
analyzed. DNA histograms having only one G0/G1
peak with a coefficient of variation (CV) less than 5%
were de® ned as diploid. DNA peaks with CV of more
than 10% were not evaluated. The histograms with
CV between 5 and 10% were accepted as wide diploid
and collected in the same group with diploid ones.
The samples were classi® ed as aneuploid if there
were at least two distinct Go/G1 peaks, the latter
having at least 10% of the total count. Cell cycle
analyses were performed by MODFIT software of
Becton & Dickinson. DNA histograms having CV of
more than 8% were not evaluated for SPF measure-
ments.
20
Statistical analysis
Correlation between the DNA ploidy and SPF
measurements and other parameters were examined
using the Pearson test and survivals were calculated
by the Kaplan± Meier method. Univariate overall
survival (OAS), disease-free survival (DFS) and
metastasis-free survival analysis (MFS) were
performed using the log-rank test. All calculations
were performed using the SPSS 7.0 for Windows
statistical package.
Results
DNA ploidy status could be determined in 44 samples
out of 47 (success rate 96%). Of these 44, S-phase
fraction could be calculated in 34 samples (77%).
Out of 44 soft tissue sarcoma samples, 21 were aneu-
ploid (two were grade 1, ® ve were grade 2 and 14
were grade 3), 23 were diploid (nine were grade 1,
nine were grade 2 and ® ve were grade 3). Ploidy
status distributions according to grade of all other
samples are shown in Table 2.
Correlation between the results of DNA analyses
and other parameters are shown in Table 3. Aneu-
ploidy was signi® cantly correlated with high grade.
Table 1. Patients characteristics
Characteristics n (%)
Male 30 (69)
Female 14 (31)
Total 44
Age: median [range] 41[12± 62]
Localization
Extremity 25 (57)
Non-extremity 19 (43)
Size
<5 cm 14
5± 10 cm 17
>10 cm 13
Grade
1 11
2 14
3 19
Histological type
Soft tissue sarcoma, not classi® ed 11
M. Schwannoma 9
Liposarcoma 7
Synovial sarcoma 5
Rhabdomyosarcoma 4
Leiomyosarcoma 3
M. ® brous histiocytoma 3
Other soft tissue tumors 2
Table 2. Results of the ¯ ow cytometric analyses
Aneuploid p SPF (mean%) p
Grade 1 2/11 (lm) 7.5
Grade 2 5/14 (lm,lt) 0.020 14.4 0.204
Grade 3 14/19 (4t) 13.2
Total 21/44 (48%) 11.1
Tetraploid (t) and multiploid (m) samples were given separately under the aneuploid group. SPFS-phase fraction.
172 M. Samur et al.Tumors with high grade or aneuploid were prone to
be metastatic in presentation.
Since sarcoma patients evaluated in this study were
histologically heterogeneous and treated with different
chemotherapy and radiotherapy protocols, survival
analyses were performed only in a subgroup of 21
patients with soft tissue sarcoma, all surgically treated
without chemotherapy or radiotherapy. In univariate
analyses, DNA ploidy was found to be signi® cant
factor for OAS and MFS. Mean OAS for aneuploid
tumors and diploid tumors were 35 and 65 months,
respectively (P=0.034). Mean MFS for aneuploid
tumors and diploid tumors were 23 and 61 months,
respectively (P=0.005;Table 4, Figs 1± 2). SPF was a
signi® cant factor for DFS. Mean DFS for tumors
with SPF£ 10% and SPF>10% were 53 and 20
months, respectively (p=0.031). Grade was a
signi® cant prognostic factor only for DFS. Mean DFS
were 52, 19 and 13 months for grade 1, 2 and 3
tumors, respectively (p=0.007) (Table 4).
Discussion
This study shows a correlation of grade and DNA
ploidy in sarcomas. Aneuploidy is found to be related
both to we ® nd that high grade and metastatic
behavior in sarcomas. In keeping with the literature,
DNA analysis may predict the aggressiveness of
sarcomas.
14 Especially in soft tissue sarcomas,
although grade is accepted as the most important
prognostic factor, criteria used to determine the grade
of a sarcoma are subjective, not standard and poorly
reproducible.
9± 11 In this respect DNA analyses with
¯ ow cytometry may be helpful for assessing the clinical
behavior of sarcomas objectively. In this way these
tumors can be separated into subsets to de® ne those
patients who should or should not be candidates for
experimental adjuvant chemotherapy.
To perform a survival analysis, we selected a
homogenous group of soft tissue sarcoma composed
of 21 patients with localized disease at presentation
Table 3. Correlation between different parameters
Factor
Correlation
coefficient p
Grade-ploidy 0.386 0.009*
Grade-metastatic
presentation
0.275 0.071
Grade-size ± 0.090 0.569
Ploidy-metastatic
presentation
0.258 0.090
Ploidy-size ± 0.231 0.140
Grade-SPF 0.247 0.159
SPF-metastatic
presentation
± 0.057 0.759
SPF-size ± 0.220 0.221
*Statistically signi® cant.
Table 4. Survival analyses of 21 soft tissue sarcoma patients treated with surgery only
Factor Not evaluable OAS DFS MFS
Ploidy
Diploid 11 65 (58± 72) 36 (18± 53)² 61 (51± 70)
Aneuploid 10 35 (22± 48) 8 (3± 12)² 23 (11± 36)
p value 0.034* 0.06 0.005*
Grade
1 9 63 (53± 73) 52 (36± 67) 62 (51± 74)
2 7 45 (31± 59) 19 (6± 32) 35 (17± 52)
3 5 45 (28± 61) 13 (5± 22) 29 (9± 48)
p value 0.632 0.007* 0.071
SPF
£ 10% 8 62 (51± 72) 53 (35± 71) 57 (42± 70)
>10% 7 44 (32± 56) 20 (8± 31) 35 (18± 52)
p value 0.420 0.031* 0.329
Surgery
Intralesional-marginal 12 46 (34± 58) 9 (3± 14)² 25 (16± 33)
En-block or radical 8 ± 41² ±
p value 0.08 0.02* 0.008*
Size
<10 cm 12 53 (45± 64) 25 (2± 47)² 41 (27± 54)
‡ 10 cm 9 60 (44± 75) 35 (7± 62)² 61 (48± 75)
p value 0.860 0.780 0.166
Localization
Extremity 14 55 (47± 64) 25 (8± 41)² 46 (33± 57)
Non-extremity 7 51 (31± 71) 11 (5± 16)² 46 (27± 66)
p value 0.453 0.800 0.704
Age
£ 40 6 53 (42± 65) 35 (3± 73)² 45 (27± 63)
>40 15 56 (42± 72) 25 (14± 35)² 48 (33± 62)
p value 0.887 0.952 0.829
² Median values, all other values are mean (months). *Statistically signi® cant. OAS, overall survival; DFS, disease-free
survival; MFS, metastasis-free survival.
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without any chemotherapy or radiotherapy. In the
analysis of this group, diploid tumors were found to
have signi® cantly longer OAS and MFS. SPF, grade
and type of surgery were signi® cant prognostic factors
for DFS. In evaluating different treatments (such as
adjuvant or neoadjuvant chemotherapy) in sarcoma
patients, the most important end point should be
MFS or OAS, since DFS can be easily affected by the
type of surgery, and the high local relapse rate may
cause a lower DFS in patients treated with inadequate
surgery. In this respect our results are notable, showing
that DNA ploidy may be as important as grade of the
tumor in evaluation of sarcomas. A similar ploidy±
survival relationship is well demonstrated in several
other studies.
21± 25Conversely, other studies ® nd SPF
a prognostic factor rather than ploidy.
26,27 Rare
studies ® nd no corelations in certain type of
sarcomas.
28 Con¯ icting results might be due to the
huge variety of histological subtypes of sarcomas or
the technical difficulties in ¯ ow cytometric DNA
analysis of sarcomas. In our study the success rate of
83% in ¯ ow cytometric DNA analysis was consistent
with others in the literature.
25Tumor necrosis is the
most important factor causing technical difficulties
in ¯ ow cytometric DNA analysis of sarcomas.
Although all samples were re-valuated histologically
before study, it is still possible that some samples
might be contaminated with necrotic debris and reac-
tive cells.
In conclusion, there is a relationship between
histological grade and ploidy in sarcomas. It appears
that low-grade tumors are generally diploid, whereas
high-grade tumors tend to be aneuploid. At least in
the sarcoma group treated with only surgery, we
showed that DNA ploidy is an important factor
Figure 1. Metastasis-free survival curve of soft tissue sarcoma patients treated with surgery only (p=0.005).
Figure 2. Overall survival curve of soft tissue sarcoma patients treated with surgery only (p=0.034).
174 M. Samur et al.predicting OAS and MFS.With improvement of the
technique and standardization with further studies,
¯ ow cytometric DNA analysis may provide an objec-
tive and reproducible prognostic variable for
comparison of series from different centers and
possibly for the selection of high-risk patients who
may be candidates for adjuvant therapy.
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